Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT: Cohort Study

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-65
SponsorFirst Affiliated Hospital Xi'an Jiaotong University

About this trial

This study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region. All patients will be followed up at the outpatient clinic once a week after transplantation until 100 days after transplantation to observe the presence of acute graft versus host disease, acute kidney damage, and major cardiovascular adverse events. Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks,4 weeks,8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.The primary objective is to explore the serum metabolic markers of acute graft versus host disease,acute kidney injury, and major adverse cardiac events within 100 days after transplantation,the secondary objective is to observe the high-risk factors for early complications.

Eligibility criteria

Qualifiers

Age ≤ 65 years old;

Disqualifiers

CREA or BUN higher than the normal upper limit value before transplantation;

Trial design

Treatments tested in this trial

  • Serum metabolomics sequencing

Treatment groups

500 Participants
are divided into 1 treatment group

Locations

This trial has no locations